Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DPX-E7 in HPV16-related cancers
NCT02865135Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2017
- Primary completion
- Oct 2019
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of DPX-E7 in oropharyngeal cancer, Cervical Cancer (CC) and anal cancer, sponsored by Dana-Farber Cancer Institute. Primary endpoints: Dose Limiting Toxicity at 50 days, Treatment-Related Adverse Event Rate at 2.92 months and 1 more. Started Mar 2017; status: completed.
02
Drugs
DPX-E7
03
Conditions
oropharyngeal cancerCervical Cancer (CC)anal cancer
Beyond the preview
Go deeper on NCT02865135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02865135.